tirzepatide study versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Cardiovascular outcomes of semaglutide and

GLP-1 receptor agonists, including semaglutide, are known to improve multiple cardiovascular risk factors, such as blood pressure, lipid profiles, inflammation, body weight, central adiposity, and glycemic control, even in non-diabetic or prediabetic people

Rare but important side effects to know about include the stomach emptying too slowly, which can lead to gastroparesis in people with prior stomach issues

Heart Failure: GLP-1 agonists reduce the risk of heart failure and increase survival rates in patients with existing heart failure

The underlying biology has not been altered. Appetite can increase Decreasing appetite and quieting food noise and cravings are among the key reasons experts say Zepbound and Mounjaro help people lose weight

But heres the kicker: it works best when used as part of a comprehensive, supervised plan